Clinical Trial Update: A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 study comparing two intermittent dosing schedules of duvelisib in indolent non-Hodgkin lymphoma has completed, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: SecuraBio | Conditions: Indolent Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19